Autolus Therapeutics plc

Autolus Therapeutics plc

AUTL · Nasdaq

Autolus Therapeutics plc (AUTL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Autolus Therapeutics plc in 2026. The next earnings report is expected on October 29, 2026.

Earnings calendar

Next earnings date

29 Oct 2026

In 68 days

EPS estimate

-0.19

Revenue estimate

35.5M

Past earnings

11 Aug 2026
EPS actual
-0.15 (+22.8%)
estimate -0.19
Revenue actual
45.7M (+18.5%)
estimate 38.6M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
14 May 2026
EPS actual
-0.27 (-6.7%)
estimate -0.25
Revenue actual
26.2M (-0.2%)
estimate 26.3M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
27 Mar 2026
EPS actual
-0.34 (-30.8%)
estimate -0.26
Revenue actual
24.3M (+1.6%)
estimate 23.9M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Nov 2025
EPS actual
-0.30 (-39.9%)
estimate -0.21
Revenue actual
21.2M (-3.9%)
estimate 22.1M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Autolus Therapeutics plc beat consensus estimates in its latest earnings report, with EPS of $-0.15 topping the $-0.1943 estimate and revenue of $45.69 million exceeding expectations by 18.5%. In the prior report, both EPS and revenue missed expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Country
Great Britain
Exchange
Nasdaq
CEO
Christian Martin Itin
Employees
647
IPO date
22 Jun 2018
ISIN
US05280R1005
Website
autolus.com

Frequently asked questions

When does Autolus Therapeutics plc (AUTL) next report earnings?

Autolus Therapeutics plc (AUTL) is scheduled to report earnings on October 29, 2026.

What was Autolus Therapeutics plc's most recent earnings date?

Autolus Therapeutics plc (AUTL) last reported earnings on August 11, 2026.

Where is Autolus Therapeutics plc stock listed?

Autolus Therapeutics plc (AUTL) is listed on Nasdaq.